chloroquine and derivatives for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
infections other than COVID-19 meta-analysis
Borges		RCT	chloroquine and derivatives	placebo	infections other than COVID-19	some concern	63/66	suggested	suggested 29.8-fold increase in clinical improvement with a moderate degree of certainty due to some concern in risk of bias
Paton NCT01078779		RCT	chloroquine and derivatives	placebo	infections other than COVID-19	low	757/749	inconclusive	inconclusive 54 % increase in Influenza-like infection (PE) with a high degree of certainty due to low risk of bias
Tricou		RCT	chloroquine and derivatives	placebo	infections other than COVID-19	low	278/276	inconclusive
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

infections other than COVID-19 meta-analysis